Business Context and Reporting Period
This Form 8-K is filed by Landec Corporation (not Lifecore Biomedical, Inc., as indicated in the metadata) for the event date of September 1, 2004. The filing reports the entry into a material definitive agreement and the creation of a direct financial obligation by Apio, Inc., a subsidiary of Landec, and Cal Ex Trading Company, a wholly-owned subsidiary of Apio.
Key Financial Metrics and Debt Structure
The filing details a new $16.0 million credit facility with Wells Fargo Bank, National Association, secured by substantially all assets of Apio and Cal Ex. Landec Corporation provided an unconditional continuing guaranty for these obligations.
- Working Capital Line: $10.0 million total (includes a $3.0 million sub-facility for Cal Ex). Due in full on August 31, 2006.
- Equipment Line: $6.0 million total.
- Initial Drawdown: $1.2 million borrowed immediately on September 1, 2004, to refinance existing indebtedness.
- Remaining Equipment Capacity: $4.8 million available for up to four advances for capital expenditures.
- Interest Rates: Borrowers may choose between a fluctuating prime rate or a fixed rate (LIBOR + 2.00% to 2.25% depending on the facility and timing).
Material Changes and Covenants
The primary material change is the establishment of the new credit facility and the associated financial covenants that Apio, Cal Ex, and Apio Cooling must maintain while obligations are outstanding:
- EBITDA Coverage Ratio: Must maintain a minimum of 1.50:1.00 on a trailing 12-month basis.
- Tangible Net Worth: Must meet minimum thresholds ranging from $17.0 million (August 2004) to $19.5 million plus 75% of cumulative net income thereafter.
- Minimum Net Income: Must achieve specific consolidated net income levels by fiscal quarter ends (e.g., $750,000 by August 31, $2.9 million by May 31).
- Capital Expenditures: Limited to $6.0 million aggregate per fiscal year.
- Debt-to-Equity: Total Liabilities to Tangible Net Worth ratio must not exceed 1.50:1.00.
Guidance, Risks, and Contingencies
The filing does not provide forward-looking revenue guidance or management commentary on future business performance beyond the terms of the credit agreement. However, it outlines significant risks associated with the new debt:
- Events of Default: If any events of default occur, Wells Fargo may terminate the credit facilities and declare all obligations immediately due and payable.
- Covenant Compliance: Failure to meet the strict EBITDA, Net Income, or Tangible Net Worth covenants could trigger a default.
Investor Verification Checklist
- Verify the current EBITDA Coverage Ratio and Tangible Net Worth of Apio to ensure compliance with the new 1.50:1.00 covenants.
- Confirm the status of the $1.2 million refinancing and whether the remaining $4.8 million equipment line has been utilized.
- Review the consolidated Net Income projections to ensure the subsidiary can meet the quarterly minimums (e.g., $2.9 million by May 31).
- Assess the impact of the Landec Corporation guaranty on the parent company's balance sheet and liquidity.
- Note that the filing metadata listed "LIFECORE BIOMEDICAL, INC." but the document text clearly identifies the registrant as LANDEC CORPORATION.